Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. We believe there’s a better way to safely and effectively bring real relief to patients, advancing accessible therapies to prescribers and payers, and providing peace of mind to parents and caregivers. Verrica is focused on innovation, changing the narrative around viral skin diseases, and making treatment a more efficient process for both physicians and patients.
Headquartered in West Chester, Pennsylvania, Verrica was founded in 2013. We are led by a seasoned management team with extensive pharmaceutical industry experience, ranging from drug development through commercialization, including collectively launching more than 50 products. VP-102, our lead product candidate, is a proprietary drug-device combination of our topical solution of cantharidin, a widely recognized, naturally sourced agent to treat topical dermatological conditions, clinically administered through our single-use precision applicator. We are initially developing VP-102 for the treatment of molluscum contagiosum, a highly contagious and primarily pediatric viral skin disease, and common warts. There are currently no products approved by the US Food and Drug Administration; nor is there an established standard of care for either of these diseases, resulting in significantly underserved populations in two of the largest unmet needs in dermatology. If approved, VP-102 will be marketed in the United States under the conditionally accepted brand name, YCANTH ™.
The Company has also entered into an exclusive worldwide license agreement with Lytix Biopharma AS (“Lytix”) to develop and commercialize LTX-315 for dermatologic oncology indications. Verrica intends to focus initially on basal cell and squamous cell carcinomas as the lead indications for development. LTX-315 is a first-in-class oncolytic peptide that is injected directly into a tumor to induce immunogenic cell death. The compound has demonstrated positive tumor-specific immune cell responses in multi-indication Phase I/II oncology trials.
